What side effects are associated with this type of intervention?

Common treatments for depression, such as SSRIs (e.g., fluoxetine) and SNRIs (e.g., duloxetine), often have side effects including nausea, headache, dry mouth, dizziness, insomnia, and sexual dysfunction. Some antidepressants, like tricyclics, may also cause weight gain, constipation, and blurred vision. Anti-inflammatory properties of certain antidepressants can lead to additional side effects like gastrointestinal issues and increased risk of bleeding. It is important to discuss these potential side effects with a healthcare provider to manage and mitigate them effectively.

What prior FDA approvals exist?

The FDA has approved several classes of antidepressants for the treatment of depression, including selective serotonin reuptake inhibitors (SSRIs) like fluoxetine and sertraline, serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine and venlafaxine, and atypical antidepressants like bupropion. Some antidepressants, like duloxetine, have shown efficacy in treating conditions with an inflammatory component, such as chronic pain, which suggests potential anti-inflammatory properties. While specific FDA approvals for antidepressants with primary anti-inflammatory effects are limited, ongoing research continues to explore this therapeutic avenue.

What other types of research exist?

Promising novel alternatives to antidepressants with anti-inflammatory properties for depression treatment in 2024 include psilocybin-assisted psychotherapy, MDMA-assisted psychotherapy, and ketamine. These treatments have shown efficacy in clinical trials for treatment-resistant depression and other psychiatric conditions.

← Back to Search

Antidepressants for Gum Disease in Patients With Depression

N/A

Waitlist Available

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

At least 18 years old

Having moderate to severe periodontal disease according to AAP definition (teeth ≥5 mm PD and ≥3 mm CAL)

Must not have

Non-English speaking

Any dental condition that requires immediate treatment, such as emergency care

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 1 week

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing if antidepressants can help reduce gum inflammation in people with both gum disease and depression. Researchers will collect various samples to study the connection between oral and body inflammation. The goal is to see if treating depression can also improve gum health.

Who is the study for?

This trial is for adults who are patients at the UAB Dental School with moderate to severe gum disease, as defined by specific dental measurements. It's open to those on antidepressants and those not suffering from depression but excludes non-English speakers, smokers, immunocompromised individuals, and anyone taking certain anti-inflammatory drugs or medications that could affect gum health.

What is being tested?

The study is testing if antidepressants can lessen gum inflammation in people with periodontal disease. Participants will undergo standard periodontal surgery while their inflammatory markers are monitored to see if there's a difference between those with and without depression.

What are the potential side effects?

While the document doesn't list specific side effects of the intervention (periodontal surgery), common ones may include swelling, bleeding, pain at the site of surgery, infection risk, and temporary discomfort during eating or brushing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have severe gum disease with deep pockets and gum recession.

Select...

I have at least 18 teeth, not counting wisdom teeth.

Select...

I am scheduled for a dental surgery soon.

Select...

I have chronic gum disease and do not suffer from depression.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not speak English.

Select...

I need immediate dental care for a condition.

Select...

I regularly take anti-inflammatory medication, but not more than 325 mg of aspirin daily.

Select...

My immune system is weakened.

Select...

I am under 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 1 week

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 1 week

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 1 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Gingival crevicular fluid (GCF)

Secondary study objectives

Plaque

Other study objectives

Blood Serum

Patient Health Questionnaire 8 (PHQ8)

Soft tissue

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Active Control

Group I: Chronic Periodontitis and Depression MedicationsActive Control1 Intervention

Patients with clinically diagnosed depression taking (SSRIs, NDRIs, SNRIs, tricyclic antidepressants) and with chronic periodontitis

Group II: Chronic PeriodontitisActive Control1 Intervention

Patients without depression, not taking any antidepressants and with chronic periodontitis

Group III: Chronic Periodontitis without Depression MedicationsActive Control1 Intervention

Patients with clinically diagnosed depression not taking any antidepressants (SSRIs NDRIs, SNRIs and Tricyclic antidepressants) and with chronic periodontitis

0 / 10Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for depression include pharmacotherapy and psychotherapy. Pharmacological treatments often involve antidepressants such as SSRIs, SNRIs, tricyclic antidepressants, and psychostimulants. These medications primarily work by altering neurotransmitter levels in the brain, such as serotonin, norepinephrine, and dopamine, which are crucial for mood regulation. Some antidepressants also exhibit anti-inflammatory properties, which can be beneficial as inflammation is increasingly recognized as a contributing factor in depression. Psychotherapeutic approaches, such as cognitive-behavioral therapy (CBT) and interpersonal therapy, focus on changing negative thought patterns and improving interpersonal relationships. Understanding these mechanisms is vital for patients, as it helps tailor treatments to individual needs, potentially improving outcomes and reducing symptoms more effectively.

Curcumin Protects Against Chronic Stress-induced Dysregulation of Neuroplasticity and Depression-like Behaviors via Suppressing IL-1β Pathway in Rats.